2006
Ken Li joined Chiral Quest (Jiashan) Co. as General Manager. He is leading CQJ to the next level. Projects are running smoothly. Globle partnership has been establishing. Kilo-lab. is under construction. Many job openning has been created. US standard operations under implementation.
2005
Company signed license agreement with Merck to provide proprietary chiral products
China facility commences operations
2004
Chiral Quest was renamed VioQuest Pharmaceuticals Inc. and began trading under the symbol VQPH. The company announced it would concentrate on acquiring, developing and commercializing human therapeutics in addition to its chiral ventures
Chiral Quest obtained patents for the following: KetalPhos
New production facility in Jiashan, China expanded capacity for the competitive and cost effective manufacturing of raw materials and chiral building blocks
C-3 TunePhos available for commercial shipment; Pheonix Chemicals Ltd. is the first receive commercial quantities of C-3 TunePhos
Pfizer Pharmaceuticals, a leading pharmaceutical manufacturer and DSM Pharma Chemicals, a leading custom chemical manufacturer, employ certain Chiral Quest catalytic products and technologies in their manufacturing
Distribution of chiral catalysts and ligands expanded through agreements with: Aventium Technologies; Strem Chemicals Inc., Sigma-Aldrich and Selectchemie AG
2003
Chiral Quest Inc. completes reverse merger with Minnesota-based Surg II, Inc.
Chiral Quest receives patents for: Biphane, f-Biphane, CN-TunePhos, Ferocene Amide Phosphine, the DIOP ligand family, and Ortho-substituted chiral biaryl phosphine ligands
2000
Chiral Quest LLC obtained exclusive worldwide rights to chiral patents based on Pennsylvania State Research Foundation’s research on asymmetrical catalysis and began commercial development of asymmetrical products for the life sciences industry
